Patents by Inventor Mathew Mulhern

Mathew Mulhern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
    Patent number: 11512092
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: November 29, 2022
    Assignee: AbbVie Inc.
    Inventors: Ayman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew Mulhern, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder
  • PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
    Publication number: 20220281882
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-?]pyrrolo[2.3-]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis), kits, methods of synthesis, and products-by-process.
    Type: Application
    Filed: February 9, 2022
    Publication date: September 8, 2022
    Inventors: Ayman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew Mulhern, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder, Aileen L. Pangan, Jaclyn Kay Anderson, In-Ho Song, Jose Jeffrey V. Enejosa
  • PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
    Publication number: 20220267342
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).
    Type: Application
    Filed: May 2, 2022
    Publication date: August 25, 2022
    Inventors: Ayman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew Mulhern, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder
  • PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
    Publication number: 20220251101
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).
    Type: Application
    Filed: April 11, 2022
    Publication date: August 11, 2022
    Inventors: Ayman ALLIAN, Jayanthy JAYANTH, Mohamed-Eslam F. MOHAMED, Mathew MULHERN, Fredrik Lars NORDSTROM, Ahmed A. OTHMAN, Michael J. ROZEMA, Lakshmi BHAGAVATULA, Patrick J. MARROUM, Peter T. MAYER, Ahmad Y. SHEIKH, Thomas B. BORCHARDT, Ben KLÜNDER
  • PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
    Publication number: 20220073530
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis), kits, methods of synthesis, and products-by-process.
    Type: Application
    Filed: November 16, 2021
    Publication date: March 10, 2022
    Inventors: Ayman ALLIAN, Jayanthy JAYANTH, Mohamed-Eslam F. MOHAMED, Mathew MULHERN, Fredrik Lars NORDSTROM, Ahmed A. OTHMAN, Michael J. ROZEMA, Lakshmi BHAGAVATULA, Patrick J. MARROUM, Peter T. MAYER, Ahmad Y. SHEIKH, Thomas B. BORCHARDT, Ben KLÜNDER
  • Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
    Patent number: 11198697
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: December 14, 2021
    Assignee: AbbVie Inc.
    Inventors: Ayman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew Mulhern, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder
  • Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
    Patent number: 11186584
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: November 30, 2021
    Assignee: AbbVie Inc.
    Inventors: Ayman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew Mulhern, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder
  • PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
    Publication number: 20210309667
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Application
    Filed: April 14, 2021
    Publication date: October 7, 2021
    Inventors: Ayman ALLIAN, Jayanthy JAYANTH, Mohamed-Eslam F. MOHAMED, Mathew MULHERN, Fredrik Lars NORDSTROM, Ahmed A. OTHMAN, Michael J. ROZEMA, Lakshmi BHAGAVATULA, Patrick J. MARROUM, Peter T. MAYER, Ahmad Y. SHEIKH, Thomas B. BORCHARDT, Ben KLÜNDER
  • PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-alpha]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
    Publication number: 20170129902
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Application
    Filed: October 17, 2016
    Publication date: May 11, 2017
    Inventors: Aymen Allian, Jayanthy Jayanth, Mohamed-Eslam Mohamed, Mathew Mulhern, Lars Fredrick Nordstroem, Ahmed Othman, Michael Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer
  • Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
    Publication number: 20080064717
    Abstract: The present invention relates to compounds of formula (I): wherein R1, R3, X, Q, Z, A, 9, m, and n are defined herein Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
    Type: Application
    Filed: May 17, 2007
    Publication date: March 13, 2008
    Inventors: Rajesh Iyengar, Gang Zhao, Jennifer Freeman, Ju Gao, Andrew Judd, Philip Kym, John Lynch, Mathew Mulhern, Andrew Souers
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050277638
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: December 22, 2004
    Publication date: December 15, 2005
    Inventors: Andrew Souers, Christine Collins, Ju Gao, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Dariusz Wodka
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050209274
    Abstract: The present invention is directed to compounds of formula (I), which antagonize of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: February 25, 2005
    Publication date: September 22, 2005
    Inventors: John Lynch, Christine Collins, Jennifer Freeman, Ju Gao, Rajesh Iyengar, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Andrew Souers, Gang Zhao, Dariusz Wodka
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050187387
    Abstract: The present invention is directed to compounds of formula (I), which antagonize of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: February 25, 2004
    Publication date: August 25, 2005
    Inventors: John Lynch, Christine Collins, Jennifer Freeman, Ju Gao, Rajesh Iyengar, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Andrew Souers, Gang Zhao
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050187279
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: December 22, 2004
    Publication date: August 25, 2005
    Inventors: Andrew Souers, Christine Collins, Ju Gao, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Dariusz Wodka
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050137187
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: December 23, 2003
    Publication date: June 23, 2005
    Inventors: Andrew Souers, Christine Collins, Ju Gao, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Dariusz Wodka
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050137243
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: December 23, 2003
    Publication date: June 23, 2005
    Inventors: Andrew Souers, Christine Collins, Ju Gao, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Anil Vasudevan, Dariusz Wodka